Pritelivir mesylate
规格
| Cas Number | 1428333-96-3 |
| 规格或纯度 | ≥99% |
| 纯度 | ≥99% |
| 包装 | 100mg 或 50mg 或 10mg 或 5mg 或 25mg |
产品信息
| 品牌 | 阿拉丁 |
| 溶解性 | DMSO : 83.33 mg/mL (167.13 mM; Need ultrasonic) |
| 过滤标签 | HSV,Anti-infection |
| 储存温度 | 2-8°C储存,干燥 |
| 运输条件 | 冰袋运输 |
| 生化和生理学机理 | 甲磺酸普利替韦（BAY 57-1293 mesylate）是一种病毒螺旋酶-primase复合物抑制剂，在体外和单纯疱疹病毒（HSV）感染的动物模型中表现出抗病毒活性。甲磺酸普立立韦对单纯疱疹病毒（HSV）具有抗病毒活性。 |
| 英文描述 |
Pritelivir mesylate (BAY 57-1293 mesylate), an inhibitor of the viral helicase-primase complex , exhibits antiviral activity in vitro and in animal models of herpes simplex virus ( HSV ) infection . Pritelivir mesylate is active against herpes simplex virus types 1 and 2 ( HSV-1 and HSV-2 ) with the IC 50 of 0.02 μM against HSV1-2 In Vivo Pritelivir is the first in a class of antiviral agents that inhibit HSV replication by targeting the viral helicase–primase enzyme complex. Pritelivir (0.03-45 mg/kg) significantly increases survival. Pritelivir (0.3-30 mg/kg) reduces mortality against HSV-1, E-377. Pritelivir has potent and resistance-breaking antiviral efficacy with potential for the treatment of potentially life-threatening HSV type 1 and 2 infections, including herpes simplex encephalitis. Combination therapies of Pritelivir at 0.1 or 0.3 mg/kg/dose with Acyclovir (10 mg/kg/dose) are protective when compared to the vehicle treated group against HSV-2, strain MS. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female BALB/c miceDosage: 0.03 to 45 mg/kg Administration: Administered orally, twice daily at approximately 12 h intervals, for 7 days Result: Survival was significantly increased to 80-100% as compared to the vehicle treatment. Even the lowest dose of 0.3 mg/kg was effective in increasing survival to 53%. Form:Solid IC50& Target:HSV-1 0.02 μM (IC 50 ) HSV-2 0.02 μM (IC 50 ) |